HIIFS
AUTL

Harel Insurance Investments & Financial Services’s Autolus Therapeutics AUTL Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,491
Closed -$46K – 465
2018
Q3 		$46K Buy
+1,491
New +$40.3K ﹤0.01% 340

Other funds holding AUTL

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Harel Insurance Investments & Financial Services's AUTL Position: Q4 2018 in Review

Harel Insurance Investments & Financial Services sold out of Autolus Therapeutics (AUTL) in Q4 2018, closing a stake of 1,491 shares — an estimated $46K sold.

Harel Insurance Investments & Financial Services first reported a position in AUTL in Q3 2018 and held it in 1 quarter. The position peaked at $46K in Q3 2018. 38 funds tracked by Wall St. Rank hold AUTL as of Q4 2018.

  • Harel Insurance Investments & Financial Services reported no remaining Autolus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 1,491 Autolus Therapeutics shares in Q4 2018, an estimated $46K.
  • Harel Insurance Investments & Financial Services first reported a position in Autolus Therapeutics in Q3 2018 and held it in 1 quarter.
  • Harel Insurance Investments & Financial Services's Autolus Therapeutics position peaked at $46K in Q3 2018.
  • 38 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2018.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q4 2018, filed 29 Jan 2019.